INTRODUCTION AND OBJECTIVES: The following multicenter randomized protocol aimed to evaluate the efficacy and tolerability of the combination therapy between SeR, Ly and Se (Profluss ) + tamsulosin versus monotherapies with Ser, Ly and Se (Profluss ) or tamsulosin in patients with LUTS / BPH. METHODS: From March 2011 to March 2012, 225 patients from 11 Italian centers were enrolled in this randomized, double-blind study. The inclusion criteria were: age between 55 and 80 years old, absence prostate cancer, PSA<4 ng/ml, IPSS12, prostate volume60 cc, peak flow 15 ml/s, post -void residual (PVR) <150 ml. The participants were randomized with a 1:1:1 ratio into 3 treatment arms each consisting of 75 patients: group A (Profluss 1 tablet per day for 1 year), group B (tamsulosin 0.4 mg 1 tablet a day for 1 year) and group C ( Profluss 1 tablet per day for 1 year + tamsulosin 0.4 mg 1 tablet per day for 1 year). RESULTS: Of all patients, 219 patients completed 12 months of treatment. The treatment groups were statistically balanced. At the intergroup analysis, significant differences were found between group C and group A in terms of IPSS (median change: -2, p<0.01), IPSS% (median change: -9.3, p<0.01), peak-flow (median change: 1, p ¼ 0.04), peak-flow% (median change: 10.5, p ¼ 0.02) and PVR (median change: -20.0, p¼0.001). We demonstrated a significant increase of at least 3 points in the IPSS in 71.6 % of subjects in group C when compared to group A ( 53.7 %, p ¼ 0.01) and group B (51.3 %, p ¼ 0.04), a significant decrease of 25% of the IPSS in 44.6%of patients in group Ccompared to group A ( 23.9 %, p ¼ 0.004) and group B (23.1 %, p ¼ 0.002) and a significant increase of 30 % of peak-flow in 47.30 % of patients of Group C compared to group A (29.85%, p¼0.03) and group B (30.77%, p¼0.03). Significant differences were found in terms of IPSS (median change: -2.0, p ¼ 0.002), IPSS% (median change: -9.0, p¼0.008), peakflow (median change: 0.8, p¼0.04) and peak-flow% (median change: 6.4, p¼0.02) between group C and group B. No difference between the two groups in terms of PVR (p¼0.23). CONCLUSIONS: In this multicenter, randomized, double-blind study the combination therapy with Ser-Se-Ly + tamsulosin 0.4 mg for 1 year was demonstrated to be more effective than the individual monotherapies in terms of reduction of the symptom score (IPSS) and in terms of increasing the Qmax in patients suffering from LUTS / BPH of moderate to severe

SERENOA REPENS, LYCOPENE AND SELENIUM VS. TAMSULOSIN IN THE TREATMENT OF LUTS / BPH: AN ITALIAN MULTICENTER RANDOMIZED COMPARATIVE STUDY BETWEEN SINGLE OR COMBINATION THERAPIES. (PROCOMB STUDY) / Giuseppe Morgia; Giorgio Ivan Russo; Salvatore Voce; Marcello Gentile; Antonella Giannantoni; Franco Blefari; Marco Carini; Andrea Minervini; Andrea Ginepri; Giuseppe Salvia; Giuseppe Vespasiani; Cimino Sebastiano; Rosalinda Allegro; Zaira Collura; Eugenia Fragala; Salvatore Arnone; Rosaria Maria Pareo. - In: THE JOURNAL OF UROLOGY. - ISSN 0022-5347. - STAMPA. - 191:(2014), pp. 669-669.

SERENOA REPENS, LYCOPENE AND SELENIUM VS. TAMSULOSIN IN THE TREATMENT OF LUTS / BPH: AN ITALIAN MULTICENTER RANDOMIZED COMPARATIVE STUDY BETWEEN SINGLE OR COMBINATION THERAPIES. (PROCOMB STUDY)

CARINI, MARCO;MINERVINI, ANDREA;
2014

Abstract

INTRODUCTION AND OBJECTIVES: The following multicenter randomized protocol aimed to evaluate the efficacy and tolerability of the combination therapy between SeR, Ly and Se (Profluss ) + tamsulosin versus monotherapies with Ser, Ly and Se (Profluss ) or tamsulosin in patients with LUTS / BPH. METHODS: From March 2011 to March 2012, 225 patients from 11 Italian centers were enrolled in this randomized, double-blind study. The inclusion criteria were: age between 55 and 80 years old, absence prostate cancer, PSA<4 ng/ml, IPSS12, prostate volume60 cc, peak flow 15 ml/s, post -void residual (PVR) <150 ml. The participants were randomized with a 1:1:1 ratio into 3 treatment arms each consisting of 75 patients: group A (Profluss 1 tablet per day for 1 year), group B (tamsulosin 0.4 mg 1 tablet a day for 1 year) and group C ( Profluss 1 tablet per day for 1 year + tamsulosin 0.4 mg 1 tablet per day for 1 year). RESULTS: Of all patients, 219 patients completed 12 months of treatment. The treatment groups were statistically balanced. At the intergroup analysis, significant differences were found between group C and group A in terms of IPSS (median change: -2, p<0.01), IPSS% (median change: -9.3, p<0.01), peak-flow (median change: 1, p ¼ 0.04), peak-flow% (median change: 10.5, p ¼ 0.02) and PVR (median change: -20.0, p¼0.001). We demonstrated a significant increase of at least 3 points in the IPSS in 71.6 % of subjects in group C when compared to group A ( 53.7 %, p ¼ 0.01) and group B (51.3 %, p ¼ 0.04), a significant decrease of 25% of the IPSS in 44.6%of patients in group Ccompared to group A ( 23.9 %, p ¼ 0.004) and group B (23.1 %, p ¼ 0.002) and a significant increase of 30 % of peak-flow in 47.30 % of patients of Group C compared to group A (29.85%, p¼0.03) and group B (30.77%, p¼0.03). Significant differences were found in terms of IPSS (median change: -2.0, p ¼ 0.002), IPSS% (median change: -9.0, p¼0.008), peakflow (median change: 0.8, p¼0.04) and peak-flow% (median change: 6.4, p¼0.02) between group C and group B. No difference between the two groups in terms of PVR (p¼0.23). CONCLUSIONS: In this multicenter, randomized, double-blind study the combination therapy with Ser-Se-Ly + tamsulosin 0.4 mg for 1 year was demonstrated to be more effective than the individual monotherapies in terms of reduction of the symptom score (IPSS) and in terms of increasing the Qmax in patients suffering from LUTS / BPH of moderate to severe
2014
Giuseppe Morgia; Giorgio Ivan Russo; Salvatore Voce; Marcello Gentile; Antonella Giannantoni; Franco Blefari; Marco Carini; Andrea Minervini; Andrea Ginepri; Giuseppe Salvia; Giuseppe Vespasiani; Cimino Sebastiano; Rosalinda Allegro; Zaira Collura; Eugenia Fragala; Salvatore Arnone; Rosaria Maria Pareo
File in questo prodotto:
File Dimensione Formato  
PD23-07.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 42.78 kB
Formato Adobe PDF
42.78 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1056780
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact